Bortezomib-induced acute pancreatitis: Case report and review of the literature
- 15 December 2014
- journal article
- case report
- Published by SAGE Publications in Journal of Oncology Pharmacy Practice
- Vol. 22 (2) , 332-334
Abstract
Acute pancreatitis is a rare complication of chemotherapy agents. We describe the case of a patient with multiple myeloma who developed acute pancreatitis after treatment with bortezomib, a proteasome inhibitor commonly used in the treatment of this disease. We reviewed the available medical literature on this topic, and found other seven similar cases, all after intravenous bortezomib. Our case is the first one occurring with the subcutaneous route of administration.Keywords
This publication has 10 references indexed in Scilit:
- Bortezomib in Multiple Myeloma: Systematic Review and Clinical ConsiderationsCurrent Oncology, 2014
- An unusual complication of bortezomib therapy: Acute pancreatitisIndian Journal of Nephrology, 2014
- Bortezomib-induced acute pancreatitis in a patient with multiple myelomaLeukemia & Lymphoma, 2013
- Acute pancreatitis caused by bortezomibPancreatology, 2013
- The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of BortezomibCurrent Pharmaceutical Design, 2011
- Drug-Induced PancreatitisDrug Safety, 2008
- Drug-Induced Acute Pancreatitis: An Evidence-Based ReviewClinical Gastroenterology and Hepatology, 2007
- Drug-Induced PancreatitisJournal of Clinical Gastroenterology, 2005
- Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior TherapyThe Oncologist, 2003
- Drug induced acute pancreatitis: incidence and severity.Gut, 1995